 |
Jan 25, 2010
Threshold Presents Clinical Trial Data From a Phase 1/2 Clinical Trial of TH-302 at ASCO Gastrointestinal Conference |
| |
REDWOOD CITY, Calif., Jan 25, 2010 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the 2010 Gastrointestinal Cancers Symposium that took place in Orlando, Florida from...
|
|
Jan 12, 2010
Threshold Pharmaceuticals Provides Clinical Development Update at J.P. Morgan Healthcare Conference |
| |
REDWOOD CITY, Calif., Jan 12, 2010 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results are being presented at the 28th Annual J.P. Morgan Healthcare Conference taking place in San Francisco...
|
|
Jan 5, 2010
Threshold to Present at J.P. Morgan Healthcare Conference |
| |
REDWOOD CITY, Calif., Jan 5, 2010 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced that Dr. Barry Selick, Threshold's chief executive officer, will present at the J.P. Morgan 28th Annual Healthcare Conference on Thursday, January 14, at 1:00 p.m. Pacific Time. The conference will take place at...
|
|
Dec 7, 2009
Threshold Pharmaceuticals Announces Preclinical Multiple Myeloma Data |
| |
REDWOOD CITY, Calif., Dec 7, 2009 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced preclinical results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented today at the American Society of Hematology (ASH) Meeting being held December 5 to 8, 2009,...
|
|
Nov 18, 2009
Threshold Pharmaceuticals Presents Interim Prostate Cancer Data From Early Stage Trials of TH-302 |
| |
REDWOOD CITY, Calif., Nov 18, 2009 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented yesterday at the AACR-NCI-EORTC International Conference on Molecular Targets and Cance...
|
|
Nov 16, 2009
Threshold to Present at Lazard Capital Markets Healthcare Conference |
| |
REDWOOD CITY, Calif., Nov 16, 2009 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced that Dr. Barry Selick, Threshold's chief executive officer, will present at the Lazard Capital Markets 6th Annual Healthcare Conference on Tuesday, November 17, at 2:40 p.m. Eastern Time. The conference is taki...
|
|
Nov 12, 2009
Threshold Pharmaceuticals Announces Clinical Development Results for Cancer Candidate TH-302 |
| |
REDWOOD CITY, Calif., Nov 12, 2009 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced a presentation related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The presentation was made at the Chemotherapy Foundation Symposium taking place in New York City from November 10 to 14, 2...
|
|
Nov 6, 2009
Threshold Pharmaceuticals Presents Interim Data From a Phase 1/2 Clinical Trial of TH-302 at Sarcoma Meeting |
| |
REDWOOD CITY, Calif., Nov 6, 2009 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the 15th Annual Connective Tissue Oncology Society (CTOS) Meeting taking place in Mia...
|
|
Nov 5, 2009
Threshold Pharmaceuticals Reports Third Quarter 2009 Financial Results |
| |
REDWOOD CITY, Calif., Nov 5, 2009 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today reported financial results for the third quarter ended September 30, 2009.
The net loss for the third quarter of 2009 was $6.2 million compared to $4.6 million for the third quarter of 2008.
Research and developme...
|
|
Oct 15, 2009
Threshold Pharmaceuticals Licenses Glufosfamide to Eleison Pharmaceuticals |
| |
REDWOOD CITY, Calif. and PRINCETON, N.J., Oct 15, 2009 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), and Eleison Pharmaceuticals, Inc., today announced the execution of a licensing agreement granting Eleison Pharmaceuticals exclusive worldwide rights to glufosfamide. Glufosfamide is a novel small molecule...
|
|
Oct 8, 2009
Threshold Pharmaceuticals Presents Interim Data From a Phase 1/2 Clinical Trial of TH-302 At Melanoma Conference |
| |
REDWOOD CITY, Calif., Oct 8, 2009 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the Perspectives in Melanoma XIII Conference taking place in Baltimore, Maryland from...
|
|
Oct 6, 2009
Threshold Pharmaceuticals Completes $35 Million Private Equity Financing |
| |
REDWOOD CITY, Calif., Oct 6, 2009 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today announced the completion of its previously announced private placement of common stock and warrants. Investors in the offering purchased units consisting of one share of common stock and a warrant to purchase 0.4 of a sh...
|
|
Sep 30, 2009
Threshold Pharmaceuticals Announces Private Equity Financing of $35 Million |
| |
REDWOOD CITY, Calif., Sep 30, 2009 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today announced that it has entered into a securities purchase agreement with a select group of new investors that includes Federated Kaufmann Fund ("Federated"), Frazier Healthcare Ventures and Great Point Partners, LLC plus...
|
|
Sep 21, 2009
Threshold Pharmaceuticals Provides Clinical Trial Update From a Complete Phase 1/2 Clinical Trial of TH-302 in Combination With Chemotherapy |
| |
REDWOOD CITY, Calif., Sep 21, 2009 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq: THLD) today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the 15th Congress of the European CanCer Organisation (ECCO) and 34th Congress of t...
|
|
Sep 18, 2009
Threshold Pharmaceuticals Announces a Presentation At the ECCO/ESMO Multidisciplinary Congress |
| |
REDWOOD CITY, Calif., Sep 18, 2009 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced a presentation of clinical trial results on its hypoxia-activated prodrug, TH-302. The presentation will take place at the Joint 15th Congress of the European CanCer Organisation (ECCO) and the 34th Congress of...
|
|
Aug 6, 2009
Threshold Pharmaceuticals Reports Second Quarter 2009 Financial Results |
| |
REDWOOD CITY, Calif., Aug 6, 2009 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today reported financial results for the second quarter ended June 30, 2009.
The net loss for the second quarter of 2009 was $6.2 million compared to $4.0 million for the second quarter of 2008. Research and development ex...
|
|
Aug 4, 2009
Results From TH-302 Clinical Trials Presented at International Lung Cancer Meeting |
| |
REDWOOD CITY, Calif and SCOTTSDALE, Ariz, Aug 4, 2009 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) and the Virginia G. Piper Cancer Center at Scottsdale Healthcare today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented at ...
|
|
Jun 8, 2009
Threshold Pharmaceuticals ASCO Webcast Available On Company Website |
| |
REDWOOD CITY, Calif., Jun 8, 2009 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced that a webcast of the Company's ASCO investor presentation is now available on the Company's website. The webcast, which was not available immediately due to technical difficulties, can be accessed on the Invest...
|
|
May 30, 2009
Threshold Pharmaceuticals Presents Encouraging Data From Clinical Trials of TH-302 for Solid Tumors |
| |
REDWOOD CITY, Calif., May 30, 2009 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced clinical trial results related to its clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the American Society for Clinical Oncology (ASCO) being held May 29 to June 2, 2009, at the ...
|
|
May 27, 2009
Threshold Pharmaceuticals Announces a Presentation At the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting |
| |
REDWOOD CITY, Calif., May 27, 2009 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced a presentation of clinical trial results on its hypoxia-activated prodrug, TH-302. The presentation will take place at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29 to J...
|
|
|
